Zobrazeno 1 - 10
of 34
pro vyhledávání: '"N, Sapoutzis"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Klinicheskaia meditsina. 85(7)
The purpose of the study was to investigate significance of the tumor marker pyruvate kinase Tumor M2 (Tu M2-PK), in diagnostics, monitoring of treatment, and evaluation of its effectiveness in patients with lung cancer (LC). This is an isoform of th
Publikováno v:
Anticancer research. 23(2A)
Biochemical bone markers, such as the bone isoenzyme form of alkaline phosphatase, have been used to assess the bone formation phase of bone turnover in health and disease. Skeletal metastases often occur in patients with malignancies. Recent develop
Publikováno v:
Anticancer research. 23(2A)
Circulating Tumor M2-PK serum levels were measured in 118 patients with various haematological malignancies. Using 17.5 U/ml as the cut-off level, elevated Tumor M2-PK concentrations were found in 7 out of 35 patients with acute myelocytic leukaemia,
Publikováno v:
Anticancer research. 23(2A)
Since tumor markers can be increased in the course of many benign diseases, the aim of this study was to verify if this also occurs in the course of rheumatic diseases.We investigated the incidence and characteristics of Tumor M2-PK in the EDTA-plasm
Autor:
G M, Oremek, N, Sapoutzis
Publikováno v:
Anticancer research. 23(2A)
Gastrin-releasing peptide (Pro-GRP), a member of the bombesin family of peptides, has been shown to have mitogenic activity in small cell lung carcinoma (SCLC), and to be produced by SCLC in an autocrine fashion. We investigated the usefulness of ser
Publikováno v:
Anticancer research. 23(2A)
Compared to normal tissues all tumors investigated so far and especially those with a metastatic potential overexpress an isoenzyme of the pyruvate kinase, the pyruvate kinase type tumor M2 (TU M2-PK). Because of its monomeric structure, the TU M2-PK
Publikováno v:
Anticancer research. 23(2A)
Tumor M2-PK is an isoform of the glycolytic enzyme pyruvate kinase. This isoform exists in an active tetrameric and less active dimeric form. The dimeric form is expressed by various tumor cells and can be measured in blood by a specific ELISA.We inc
Publikováno v:
Anticancer research. 20(6D)
Pyruvate kinase is one of the glycolytic key enzymes. It exists in various isoforms which are expressed in different cell types. One of these isoforms, the type Tu M2-PK, is strongly overexpressed by tumor cells and released into body fluids. The con